| Identification | More | [Name]
7-METHYLINDOLE-3-CARBOXALDEHYDE | [CAS]
4771-50-0 | [Synonyms]
3-FORMYL-7-METHYLINDOLE
7-METHYL-1H-INDOLE-3-CARBALDEHYDE
7-METHYLINDOLE-3-ALDEHYDE
7-METHYLINDOLE-3-CARBOXALDEHYDE
7-METHYLINDOLE-3-CARBOXYALDEHYDE
1H-Indole-3-carboxaldehyde, 7-methyl-(9CI)
7-Methylindole-3-carboxaldehyde 98%
7-Methyl-3-indolecarboxaldehyde
7-METHYLINDOLE-3-CARBOXALDEHYDE 98% (HPLC) | [EINECS(EC#)]
-0 | [Molecular Formula]
C10H9NO | [MDL Number]
MFCD00047170 | [Molecular Weight]
159.18 | [MOL File]
4771-50-0.mol |
| Chemical Properties | Back Directory | [Melting point ]
206-208°C | [Boiling point ]
341.0±22.0 °C(Predicted) | [density ]
1.226±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [form ]
Solid | [pka]
15.80±0.30(Predicted) | [color ]
Yellow to brown | [Sensitive ]
Air Sensitive | [BRN ]
122340 | [InChI]
InChI=1S/C10H9NO/c1-7-3-2-4-9-8(6-12)5-11-10(7)9/h2-6,11H,1H3 | [InChIKey]
KTUFZHVVJBHGKZ-UHFFFAOYSA-N | [SMILES]
N1C2=C(C=CC=C2C)C(C=O)=C1 | [CAS DataBase Reference]
4771-50-0(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [Hazard Note ]
Irritant | [HS Code ]
29339900 |
| Hazard Information | Back Directory | [Uses]
Reactant for preparation of:
- Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles as potential anticancer immunomodulators
- Antibacterial and antituberculosis agents
- Antiandrogens effective against androgen receptor mutants
- Anti-bovine viral diarrhea virus (BVDV) agents
- Receptor subtype 5 antagonists
- Glucocorticoid receptor ligands
- Necroptosis inhibitors
- Orally efficacious small-molecule sctivator of the insulin receptor
| [Uses]
Reactant for preparation of:• ;Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles as potential anticancer immunomodulators1• ;Antibacterial and antituberculosis agents2• ;Antiandrogens effective against androgen receptor mutants3• ;Anti-bovine viral diarrhea virus (BVDV) agents4• ;Receptor subtype 5 antagonists5• ;Glucocorticoid receptor ligands6• ;Necroptosis inhibitors7• ;Orally efficacious small-molecule sctivator of the insulin receptor8 |
|
|